Serum albumin as a prognostic indicator for HIV disease progression.

PubWeight™: 1.42‹?› | Rank: Top 5%

🔗 View Article (PMID 16438640)

Published in AIDS Res Hum Retroviruses on January 01, 2006

Authors

Shruti H Mehta1, Jacquie Astemborski, Timothy R Sterling, David L Thomas, David Vlahov

Author Affiliations

1: Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland 21205, USA. shmehta@jhsph.edu

Articles citing this

Characterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti -tuberculosis therapy. In Silico Pharmacol (2014) 1.41

Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr (2008) 1.26

Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells. J Virol (2008) 1.20

Association of serum albumin concentration with mortality, morbidity, CD4 T-cell reconstitution among tanzanians initiating antiretroviral therapy. J Infect Dis (2013) 1.19

Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS (2010) 1.09

Poverty, hunger, education, and residential status impact survival in HIV. AIDS Behav (2011) 1.05

Serum albumin and short-term risk for mortality and cardiovascular disease among HIV-infected veterans. AIDS (2013) 0.89

Usefulness of alternate prognostic serum and plasma markers for antiretroviral therapy for human immunodeficiency virus type 1 infection. Clin Vaccine Immunol (2007) 0.89

Potential of Spirulina Platensis as a Nutritional Supplement in Malnourished HIV-Infected Adults in Sub-Saharan Africa: A Randomised, Single-Blind Study. Nutr Metab Insights (2011) 0.86

HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. Curr HIV Res (2014) 0.82

Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrob Agents Chemother (2014) 0.81

A decrease in albumin in early SIV infection is related to viral pathogenicity. AIDS Res Hum Retroviruses (2009) 0.78

The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations. HIV Med (2013) 0.78

Serum albumin and kidney function decline in HIV-infected women. Am J Kidney Dis (2014) 0.77

Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. Open Forum Infect Dis (2015) 0.77

Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection. AIDS (2017) 0.75

Nutritional status of HIV-infected patients during the first year HAART in two West African cohorts. J Health Popul Nutr (2015) 0.75

An Evaluation of Alternative Markers to Guide Initiation of Anti-retroviral Therapy in HIV-Infected Children in Settings where CD4 Assays are not Available. J Trop Pediatr (2015) 0.75

Sex differences in the association of HIV infection with hepatic steatosis. AIDS (2016) 0.75

Case control study: magnetic resonance spectroscopy of brain in HIV infected patients. BMC Neurol (2016) 0.75

Association of Abnormal Liver Function Parameters with HIV Serostatus and CD4 Count in Antiretroviral-Naive Rwandan Women. AIDS Res Hum Retroviruses (2015) 0.75

Serum Albumin Concentrations in a Multi-Ethnic Cohort of Patients with Human Immunodeficiency Virus Infection from South East London. Biores Open Access (2015) 0.75

Prevalence of Malnutrition and Associated Factors among Hospitalized Patients with Acquired Immunodeficiency Syndrome in Jimma University Specialized Hospital, Ethiopia. Ethiop J Health Sci (2016) 0.75

Distinct Patterns of Tryptophan Maintenance in Tissues during Kynurenine Pathway Activation in Simian Immunodeficiency Virus-Infected Macaques. Front Immunol (2016) 0.75

Articles by these authors

Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53

Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90

Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62

A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet (2004) 10.87

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18

Psychological sequelae of the September 11 terrorist attacks in New York City. N Engl J Med (2002) 10.07

MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22

Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 7.58

Tuberculosis. Lancet (2003) 6.39

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13

Protection against persistence of hepatitis C. Lancet (2002) 5.94

Canadian illicit opiate users' views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse (2002) 5.65

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60

The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health (2004) 5.21

Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06

An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02

APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54

Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction (2003) 4.25

The epidemiology of post-traumatic stress disorder after disasters. Epidemiol Rev (2005) 4.09

Television images and psychological symptoms after the September 11 terrorist attacks. Psychiatry (2002) 4.07

Trends of probable post-traumatic stress disorder in New York City after the September 11 terrorist attacks. Am J Epidemiol (2003) 3.93

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78

Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72

HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56

Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46

Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev (2002) 3.45

Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44

The social epidemiology of substance use. Epidemiol Rev (2004) 3.41

A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41

Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis (2007) 3.36

Challenges and facilitating factors in sustaining community-based participatory research partnerships: lessons learned from the Detroit, New York City and Seattle Urban Research Centers. J Urban Health (2006) 3.36

Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health (2004) 3.32

Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol (2003) 3.29

Hepatitis C and progression of HIV disease. JAMA (2002) 3.15

Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep (2002) 3.14

Evaluation of an intervention to increase screening colonoscopy in an urban public hospital setting. J Urban Health (2006) 3.10

Occult hepatitis B. Lancet Infect Dis (2002) 3.09

Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06

IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02

Urban health: evidence, challenges, and directions. Annu Rev Public Health (2005) 3.02

In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01

Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00

Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99

AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med (2005) 2.97

Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78

Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71

Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis (2002) 2.68

Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67

Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64

Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61

Mental health service and medication use in New York City after the September 11, 2001, terrorist attack. Psychiatr Serv (2004) 2.58

Needlestick transmission of hepatitis C. JAMA (2002) 2.55

Cities and population health. Soc Sci Med (2005) 2.53

Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr (2007) 2.53

Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52

Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50

HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47

SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45

Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40

What predicts psychological resilience after disaster? The role of demographics, resources, and life stress. J Consult Clin Psychol (2007) 2.39

Urban built environment and depression: a multilevel analysis. J Epidemiol Community Health (2005) 2.34

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34

Urban neighborhood poverty and the incidence of depression in a population-based cohort study. Ann Epidemiol (2007) 2.33

Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol (2002) 2.29

Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS (2008) 2.28

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24

Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23

High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20

Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health (2006) 2.20

Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol (2004) 2.19

Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med (2009) 2.18

U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18

Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16

A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother (2012) 2.16

Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS (2013) 2.11

Psychological resilience after disaster: New York City in the aftermath of the September 11th terrorist attack. Psychol Sci (2006) 2.08

Neighborhood poverty and injection cessation in a sample of injection drug users. Am J Epidemiol (2010) 2.07

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05

Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis (2009) 2.04

Primary care and health insurance among women released from New York City jails. J Health Care Poor Underserved (2006) 2.04

High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: a case-control study. Drug Alcohol Depend (2002) 2.04

Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02